EGFR and neoplasm: Analysis limited to patients in whom the tumor PD-L1 expression was evaluated in tissue specimens obtained before the start of the first-line EGFR-TKI treatment showed similar results (7/10 patients (70.0%) vs. 3/12 patients (25.0%); p = 0.084, Fisher’s exact test).